Evidence map›Paper›PMID 40320493›Full record

ArticleVirchows Archiv : an international journal of pathology2026

P-cadherin overexpression is associated with early transformation of the Fallopian tube epithelium and aggressiveness of tubo-ovarian high-grade serous carcinoma.

Rita Canário, Ana Sofia Ribeiro, Inês Morgado, Ana Peixoto, Ana Barbosa, Catarina Santos, Nuno Mendes, Paula Lopes, Paula Monteiro, Ricardo Coelho and 6 more

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rita CanárioGraduate Program in Areas of Basic and Applied Biology (GABBA), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-3563-7752
Ana Sofia RibeiroCancer Metastasis, i3S-Institute for Research and Innovation in Health, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-9698-9233
Inês MorgadoCancer Metastasis, i3S-Institute for Research and Innovation in Health, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0003-0938-455X
Ana PeixotoCancer Genetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-1404-5897
Ana BarbosaCancer Genetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-2307-1018
Catarina SantosCancer Genetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-9102-757X
Nuno MendesHistology and Electron Microscopy, i3S-Institute for Research and Innovation in Health, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-0570-2277
Paula LopesCancer Biology and Epigenetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0003-0633-4143
Paula MonteiroCancer Biology and Epigenetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-3482-2307
Ricardo CoelhoOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9340-3612
Francis JacobOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031, Basel, Switzerland.ORCID http://orcid.org/0000-0002-0446-1942
Viola Heinzelmann-SchwarzOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, 4031, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4056-3225
Sara RicardoAgeing and Stress Group, i3S-Institute for Research and Innovation in Health,, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0003-4091-2226
Manuel R TeixeiraCancer Genetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-4896-5982
Carla BartoschCancer Biology and Epigenetics Group, Research Center-Portuguese Oncology Institute of Porto (CI-IPO-Porto)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto/Porto. Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0003-0646-7667
Joana ParedesCancer Metastasis, i3S-Institute for Research and Innovation in Health, University of Porto, Porto, Portugal. jparedes@i3s.up.pt.ORCID http://orcid.org/0000-0002-1076-1343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tubo-ovarian high-grade serous carcinoma (HGSC) with proficient homologous recombination (HR) DNA repair (HRP) accounts for approximately 50% of cases and is associated with platinum-resistance and poor prognosis. We hypothesize that the acquisition of hybrid phenotypes displaying both epithelial and mesenchymal (E/M) features may be involved in the malignant transformation and tumour dissemination in this subgroup. Therefore, we analysed, by digital pathology, the expression and prognostic significance of 3 classic cadherins (E-cadherin, epithelial marker; N-cadherin, mesenchymal marker; and P-cadherin, candidate marker of hybrid E/M) in 577 formalin-fixed paraffin-embedded human samples representing the putative stepwise serous carcinogenesis in the Fallopian tube epithelium (FTE). We observed a non-canonical N-to-P-cadherin switch along the carcinogenic progression, with a statistically significant overexpression of P-cadherin in pre-malignant and malignant samples, compared to the control FTE. Interestingly, this overexpression was most pronounced in precursor lesions and HGSC cells from malignant ascites. Tumours with high P-cadherin expression were significantly associated with worse overall survival, especially in the subgroup without BRCA1/2 mutations. Transient P-cadherin knock-down resulted in in vitro significant reduction of functional hybrid E/M hallmarks, namely decreased anoikis resistance, reduced collective migration and invasion in a representative platinum-resistant HRP cell line. Taken together, our results suggest that P-cadherin overexpression is an early event in the serous carcinogenesis and may be involved in hybrid E/M activation in HRP-HGSC, further supporting this adhesion molecule as a promising biomarker for this poor prognostic subgroup.

Indexed as

Biomarkers, TumorCadherinsCell Transformation, NeoplasticCystadenocarcinoma, SerousFallopian Tube NeoplasmsFallopian TubesOvarian NeoplasmsAdultAgedEpitheliumFemaleHumansMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorCadherinsCDH3Epithelial-to-mesenchymal plasticity (EMP)High-grade serous carcinomaHomologous recombinationP-cadherin

Identifiers

PMID40320493
PMCPMC12916920

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.